<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 32-year-old woman was treated for Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> diagnosed during the 22nd week of pregnancy </plain></SENT>
<SENT sid="1" pm="."><plain>Chemotherapy consisting of <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (Adriamycin), <z:chebi fb="0" ids="28445">vincristine</z:chebi>, teniposide (VM-26), <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and <z:chebi fb="2" ids="8378">prednisolone</z:chebi> (AVTEP) was given each 2.5 to 3 weeks from the time of the diagnosis until delivery in the 37th week </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="3139">Bleomycin</z:chebi> and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were also given from the 35th week </plain></SENT>
<SENT sid="3" pm="."><plain>The infant was born after an assisted vaginal delivery and was fully developed and <z:mpath ids='MPATH_458'>normal</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> respects </plain></SENT>
<SENT sid="4" pm="."><plain>This paper confirms prior reports that cytotoxic chemotherapy may safely be given during the second and third trimesters of pregnancy without adverse effects on the fetus </plain></SENT>
<SENT sid="5" pm="."><plain>To our knowledge it is the first report of the use of teniposide, a new podophyllin derivative, during pregnancy </plain></SENT>
</text></document>